{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:00:59Z","timestamp":1790179259175,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Unfallchirurgie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00113-026-01733-8","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:11:30Z","timestamp":1784110290000},"page":"666-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management\u00a0 proximaler Femurfrakturen unter Therapie mit direkten oralen Antikoagulanzien (DOAK)","Treatment of proximal femur fractures in patients on direct oral anticoagulants (DOACs)"],"prefix":"10.1007","volume":"129","author":[{"given":"Jannis","family":"Christoffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Maegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.rdc.2006.08.003","volume":"32","author":"E Dennison","year":"2006","unstructured":"Dennison\u00a0E, Mohamed\u00a0MA, Cooper\u00a0C (2006) Epidemiology of osteoporosis. Rheum Dis Clin 32:617\u2013629","journal-title":"Rheum Dis Clin"},{"key":"1733_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046175","volume":"7","author":"L Moja","year":"2012","unstructured":"Moja\u00a0L, Piatti\u00a0A, Pecoraro\u00a0V, Ricci\u00a0C, Virgili\u00a0G, Salanti\u00a0G, Germagnoli\u00a0L, Liberati\u00a0A, Banfi\u00a0G (2012) Timing matters in hip fracture surgery: patients operated within 48\u00a0hours have better outcomes: a\u00a0meta-analysis and meta-regression of over 190,000 patients. PLoS ONE 7:e46175","journal-title":"PLoS ONE"},{"issue":"1","key":"1733_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00391-018-1382-z","volume":"52","author":"K Rapp","year":"2019","unstructured":"Rapp\u00a0K, B\u00fcchele\u00a0G, Dreinh\u00f6fer\u00a0K, B\u00fccking\u00a0B, Becker\u00a0C, Benzinger\u00a0P (2019) Epidemiology of hip fractures. Z Gerontol Geriatr 52(1):10\u201316","journal-title":"Z Gerontol Geriatr"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.thromres.2015.09.017","volume":"136","author":"T Tran","year":"2015","unstructured":"Tran\u00a0T, Delluc\u00a0A, de Witt\u00a0C, Petrcich\u00a0W, Le Gal\u00a0G, Carrier\u00a0M (2015) The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thromb Res 136:962\u2013965","journal-title":"Thromb Res"},{"key":"1733_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen\u00a0A, Stecker\u00a0E, Warden\u00a0BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. JAHA 9:e017559","journal-title":"JAHA"},{"key":"1733_CR6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","volume":"27","author":"DK Rose","year":"2018","unstructured":"Rose\u00a0DK, Bar\u00a0B (2018) Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J\u00a0Stroke Cerebrovasc Dis 27:2049\u20132058","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1733_CR7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/bcp.13299","volume":"83","author":"SY Loo","year":"2017","unstructured":"Loo\u00a0SY, Dell\u2019Aniello\u00a0S, Huiart\u00a0L, Renoux\u00a0C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care: novel oral anticoagulant prescription trends. Br J Clin Pharmacol 83:2096\u20132106","journal-title":"Br J Clin Pharmacol"},{"key":"1733_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072200","volume":"9","author":"SM Tarrant","year":"2020","unstructured":"Tarrant\u00a0SM, Catanach\u00a0MJ, Sarrami\u00a0M, Clapham\u00a0M, Attia\u00a0J, Balogh\u00a0ZJ (2020) Direct oral anticoagulants and timing of hip fracture surgery. J\u00a0Clin Med 9:2200","journal-title":"J Clin Med"},{"key":"1733_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/EOR-22-0060","volume":"8","author":"PV Wall","year":"2023","unstructured":"Wall\u00a0PV, Brendon\u00a0CM, Canhaghi\u00a0NT, Kent\u00a0WT (2023) Review of perioperative outcomes and management of hip fracture patients on direct oral anticoagulants. EFFORT Open Rev 8:561\u2013571","journal-title":"EFFORT Open Rev"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","volume":"52","author":"F Scaglione","year":"2013","unstructured":"Scaglione\u00a0F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69\u201382","journal-title":"Clin Pharmacokinet"},{"issue":"Supplement E","key":"1733_CR11","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1093\/eurheartj\/suy016","volume":"20","author":"MV Huisman","year":"2018","unstructured":"Huisman\u00a0MV, Klok\u00a0FA (2018) Pharmacological properties of betrixaban. Eur Heart J Suppl 20(Supplement E):E12\u2013E15","journal-title":"Eur Heart J Suppl"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40266-018-0609-4","volume":"36","author":"KK Viktil","year":"2019","unstructured":"Viktil\u00a0KK, Lehre\u00a0I, Ranhoff\u00a0AH, Molden\u00a0E (2019) Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a\u00a0pilot study. Drugs Aging 36:65\u201371","journal-title":"Drugs Aging"},{"key":"1733_CR13","first-page":"22","volume":"103","author":"D You","year":"2021","unstructured":"You\u00a0D, Xu\u00a0Y, Ponich\u00a0B, Ronksley\u00a0P, Skeith\u00a0L, Korley\u00a0R, Carrier\u00a0M, Schneider\u00a0PS (2021) Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone Joint J 103:22\u2013233","journal-title":"Bone Joint J"},{"key":"1733_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2018.04.022","volume":"166","author":"T Frenkel Rutenberg","year":"2018","unstructured":"Frenkel Rutenberg\u00a0T, Velkes\u00a0S, Vitenberg\u00a0M, Leader\u00a0A, Halavy\u00a0Y, Raanani\u00a0P, Yassin\u00a0M, Spectre\u00a0G (2018) Thromb Res 166:106\u2013112","journal-title":"Thromb Res"},{"key":"1733_CR15","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/BOT.0000000000001329","volume":"33","author":"M Bruckbauer","year":"2019","unstructured":"Bruckbauer\u00a0M, Prexl\u00a0O, Voelkel\u00a0W, Ziegler\u00a0B, Grottke\u00a0O, Maegele\u00a0M, Sch\u00f6chl\u00a0H (2019) Impact of direct oral anticoagulants in patients with hip fractures. J\u00a0Orth Trauma 33:e8\u2013e13","journal-title":"J Orth Trauma"},{"key":"1733_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11239-016-1431-7","volume":"43","author":"DJ Seiffge","year":"2017","unstructured":"Seiffge\u00a0DJ, Traenka\u00a0C, Polymeris\u00a0A, Hert\u00a0L, Fisch\u00a0U, Peters\u00a0N, De Marchis\u00a0GM, Guzman\u00a0R, Nickel\u00a0CH, Lyrer\u00a0PA, Bonati\u00a0LH, Tsakiris\u00a0D, Engelter\u00a0S (2017) Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. J\u00a0Thromb Thrombolysis 43:112\u2013116. https:\/\/doi.org\/10.1007\/s11239-016-1431-7","journal-title":"J Thromb Thrombolysis"},{"key":"1733_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-018-0183-3","volume":"16","author":"AL Sennesael","year":"2018","unstructured":"Sennesael\u00a0AL, Larock\u00a0AS, Douxfils\u00a0J, Elens\u00a0L, Stillemans\u00a0G, Wiesen\u00a0M, Taubert\u00a0M, Dogne\u00a0JM, Spinewine\u00a0A, Mullier\u00a0F (2018) Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J 16:28. https:\/\/doi.org\/10.1186\/s12959-018-0183-3","journal-title":"Thromb J"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1503\/cjs.010021","volume":"66","author":"D You","year":"2023","unstructured":"You\u00a0D, Xu\u00a0Y, Krzyzaniak\u00a0H, Korley\u00a0R, Carrier\u00a0M, Schneider\u00a0P (2023) Safety of expedited-surgery protocols in anticoagulant-treated patients with hip fracture: a\u00a0systematic review and meta-analysis. Can J Surg 66:E170\u2013E180. https:\/\/doi.org\/10.1503\/cjs.010021","journal-title":"Can J Surg"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/a-1549-6556","volume":"122","author":"E Lindhoff-Last","year":"2022","unstructured":"Lindhoff-Last\u00a0E, Birschmann\u00a0I, Kuhn\u00a0J, Lindau\u00a0S, Konstantinides\u00a0S, Grottke\u00a0O, Nowak-Gottl\u00a0U, Lucks\u00a0J, Zydek\u00a0B, von Heymann\u00a0C, Sumnig\u00a0A, Beyer-Westendorf\u00a0J, Schellong\u00a0S, Meybohm\u00a0P, Greinacher\u00a0A, Herrmann\u00a0E, Investigators RA\u2011R (2022) Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. Thromb Haemost 122:552\u2013559. https:\/\/doi.org\/10.1055\/a-1549-6556","journal-title":"Thromb Haemost"},{"issue":"9","key":"1733_CR20","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1161\/STROKEAHA.117.017981","volume":"48","author":"M Ebener","year":"2017","unstructured":"Ebener\u00a0M, Birschmann\u00a0I, Peter\u00a0A, H\u00e4rting\u00a0F, Spencer\u00a0C, Kuhn\u00a0J, Blumenstock\u00a0G, Zuern\u00a0CS, Ziemann\u00a0U, Poli\u00a0S (2017) Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 48(9):2457\u20132463","journal-title":"Stroke"},{"issue":"3","key":"1733_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5853\/jos.2017.00395","volume":"19","author":"DJ Seiffge","year":"2017","unstructured":"Seiffge\u00a0DJ, Traenka\u00a0C, Polymeris\u00a0AA, Thilemann\u00a0S, Wagner\u00a0B, Hert\u00a0L, M\u00fcller\u00a0MD, Gensicke\u00a0H, Peters\u00a0N, Nickel\u00a0CH, Stippich\u00a0C, Sutter\u00a0R, Marsch\u00a0S, Fisch\u00a0U, Guzman\u00a0R, De Marchis\u00a0GM, Lyrer\u00a0PA, Bonati\u00a0LH, Tsakiris\u00a0DA, Engelter\u00a0ST (2017) Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice. J\u00a0Stroke 19(3):347\u2013355","journal-title":"J Stroke"},{"issue":"5","key":"1733_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack","year":"2017","unstructured":"Pollack\u00a0CV, Reilly\u00a0PA, Van Ryn\u00a0J, Eikelboom\u00a0JW, Glund\u00a0S, Bernstein\u00a0RA, Dubiel\u00a0R, Huisman\u00a0MV, Hylek\u00a0EM, Kam\u00a0CW, Kamphuisen\u00a0PW, Kreuzer\u00a0J, Levy\u00a0JH, Royle\u00a0G, Sellke\u00a0FW, Stangier\u00a0J, Steiner\u00a0T, Verhamme\u00a0P, Wang\u00a0B, Young\u00a0L, Weitz\u00a0JI (2017) Idarucizumab for dabigatran reversal-full cohort analysis. N Engl J Med 377(5):431\u2013441","journal-title":"N Engl J Med"},{"issue":"28","key":"1733_CR23","first-page":"27","volume":"16","author":"AL Sennesael","year":"2018","unstructured":"Sennesael\u00a0AL, Larock\u00a0AS, Douxfils\u00a0J, Elens\u00a0L, Stillemans\u00a0G, Wiesen\u00a0M, Taubert\u00a0M, Dogn\u00e9\u00a0JM, Spinewine\u00a0A, Mullier\u00a0F (2018) Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J 16(28):27","journal-title":"Thromb J"},{"issue":"1","key":"1733_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/trf.15560","volume":"60","author":"A Kaserer","year":"2020","unstructured":"Kaserer\u00a0A, Kiavialaitis\u00a0GE, Braun\u00a0J, Schedler\u00a0A, Stein\u00a0P, R\u00f6ssler\u00a0J, Spahn\u00a0DR, Studt\u00a0JD (2020) Impact of rivaroxaban plasma concentration on perioperative red blood cell loss. Transfusion 60(1):197\u2013205","journal-title":"Transfusion"},{"issue":"4","key":"1733_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/a-1549-6556","volume":"122","author":"E Lindhoff-Last","year":"2022","unstructured":"Lindhoff-Last\u00a0E, Birschmann\u00a0I, Kuhn\u00a0J, Lindau\u00a0S, Konstantinidis\u00a0S, Grottle\u00a0O, Nowak-G\u00f6ttl\u00a0U, Lucks\u00a0J, Zydek\u00a0B, Von Heymann\u00a0C, S\u00fcmnig\u00a0A, Beyer-Westendorf\u00a0J, Schellong\u00a0S, Meybohm\u00a0P, Greinacher\u00a0A, Herrmann\u00a0E, RADOA-Registry Investigators (Reversal agent use in patients treated with direct oral anticoagulants or vitamin K antagonists Registry) (2022) Pharmacokinetics of direct oral anticoagulants in emergency situations. Results of the prospective observational RADOA-registry. Thromb Haemost 122(4):552\u2013559","journal-title":"Thromb Haemost"},{"key":"1733_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s11739-018-1854-6","volume":"13","author":"A Tripodi","year":"2018","unstructured":"Tripodi\u00a0A, Marongiu\u00a0F, Moia\u00a0M, Palareti\u00a0G, Pengo\u00a0V, Poli\u00a0D, Prisco\u00a0D, Testa\u00a0S, Zanazzi\u00a0M (2018) The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedure. Intern Emerg Med 13:1029\u20131036","journal-title":"Intern Emerg Med"},{"key":"1733_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/imj.15007","volume":"52","author":"K Creeper","year":"2022","unstructured":"Creeper\u00a0K, Staffort\u00a0A, Reynolds\u00a0S, Samida\u00a0S, P\u2019Ng\u00a0S, Glennon\u00a0D, Seymore\u00a0H, Grove\u00a0C (2022) Outcomes and anticoagulation use for elderly patients that present with an acute hip fracture: multicentre, retrospective analysis. Intern Med J 52:418\u2013425","journal-title":"Intern Med J"},{"issue":"5","key":"1733_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.thromres.2011.01.001","volume":"127","author":"G Freyburger","year":"2011","unstructured":"Freyburger\u00a0G, MacOuillard\u00a0G, Labrouche\u00a0S, Sztark\u00a0F (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127(5):457\u2013465","journal-title":"Thromb Res"},{"issue":"16","key":"1733_CR29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel\u00a0J, Verhamme\u00a0P, Potpara\u00a0TS, Albaladejo\u00a0P, Antz\u00a0M, Desteghe\u00a0L, Haeusler\u00a0KG, Oldgren\u00a0J, Reinecke\u00a0H, Roldan-Schilling\u00a0V, Rowell\u00a0N, Sinnaeve\u00a0P, Collins\u00a0R, Camm\u00a0AJ, Heidb\u00fcchel\u00a0H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"issue":"19","key":"1733_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009807","volume":"7","author":"M Ebner","year":"2018","unstructured":"Ebner\u00a0M, Birschmann\u00a0I, Peter\u00a0A, H\u00e4rting\u00a0F, Spencer\u00a0C, Kuhn\u00a0J, Rupp\u00a0A, Blumenstock\u00a0G, Zuern\u00a0CS, Ziemann\u00a0U, Poli\u00a0S (2018) Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis. J\u00a0Am Heart Assic 7(19):e009807","journal-title":"J Am Heart Assic"},{"key":"1733_CR31","doi-asserted-by":"crossref","unstructured":"Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C, Working Group Members. Accuracy of a\u00a0rapid diagnostic test for the presence of direct oral factor\u00a0Xa or thrombin inhibitors in urine: a\u00a0multicenter trial. Thromb Haemost. 2020;120(1):132\u2013140.","DOI":"10.1055\/s-0039-1700545"},{"issue":"1","key":"1733_CR32","volume":"29","author":"K White","year":"2022","unstructured":"White\u00a0K, Faruqi\u00a0U, Cohen\u00a0A (2022) New agents for DOAC reversal: a\u00a0practical management review. Br J Cardiol 29(1):1","journal-title":"Br J Cardiol"},{"issue":"6","key":"1733_CR33","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1111\/ijlh.12870","volume":"40","author":"AS Dincq","year":"2018","unstructured":"Dincq\u00a0AS, Lessire\u00a0S, Pirard\u00a0G, Sirez\u00a0R, Guldenpfenning\u00a0M, Baudar\u00a0J, Favresse\u00a0J, Douxflis\u00a0J, Mullier\u00a0F (2018) Reduction of the turnaround time for the measurement of rivaroxaban and apixaban: assessment of the performance of a rapid centrifugation method. Int J Lab Hematol 40(6):e105\u2013e108","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"1733_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11239-016-1431-7","volume":"43","author":"DJ Seiffge","year":"2017","unstructured":"Seiffge\u00a0DJ, Traenka\u00a0C, Polymeris\u00a0A, Hert\u00a0L, Fisch\u00a0U, Peters\u00a0N, De Marchis\u00a0GM, Guzman\u00a0R, Nickel\u00a0CH, Lyrer\u00a0PA, Bonati\u00a0LH, Tsakiris\u00a0D, Engelter\u00a0S (2017) Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke. J\u00a0Thromb Thrombolysis 43(1):112\u2013116","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"1733_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0038-1668098","volume":"45","author":"J Harenberg","year":"2019","unstructured":"Harenberg\u00a0J, Schreiner\u00a0R, Hetjens\u00a0S, Weiss\u00a0C (2019) Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using DOAC dipstick. Semin Thromb Hemost 45(3):275\u2013284","journal-title":"Semin Thromb Hemost"},{"key":"1733_CR36","doi-asserted-by":"publisher","DOI":"10.1055\/a-2822-7599","author":"G Herpertz","year":"2026","unstructured":"Herpertz\u00a0G, Altmann\u00a0U, Poli\u00a0S, Sch\u00e4fer\u00a0ST (2026) Advancing Point-of-Care Analysis: The future of thromboelastographic DOAC detection: A\u00a0systematic review. Semin Thromb Hemost. https:\/\/doi.org\/10.1055\/a-2822-7599","journal-title":"Semin Thromb Hemost"},{"key":"1733_CR37","doi-asserted-by":"crossref","unstructured":"Kimmit, Siegal, Ansell. Measuring Direct Oral Anticoagulants: Pharmacodynamic vs Pharmacokinetic Assays: A\u00a0New Pharmacodynamic Assay. Medical Res Archieves 2026; 14: 1 (online)","DOI":"10.18103\/mra.v14i1.7245"},{"key":"1733_CR38","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1111\/jth.14977","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu\u00a0Y, You\u00a0D, Krzyaniak\u00a0H, Ponich\u00a0B, Ronksley\u00a0P, Skeith\u00a0L, Salo\u00a0P, Korley\u00a0R, Schneider\u00a0P, Carrier\u00a0M (2020) Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: a systematic review and meta-analysis. J\u00a0Thromb Haemost 18:2566\u20132581","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1733_CR39","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1503\/cjs.010021","volume":"66","author":"D You","year":"2023","unstructured":"You\u00a0D, Xu\u00a0Y, Krzyzaniak\u00a0H, Korley\u00a0R, Carrier\u00a0M, Schneider\u00a0P (2023) Safety of expedited-surgery protocols in anticoagulant-treated patients with hip fracture: a systematic review and meta-analysis. Can J Surg 66(2):E170\u2013E180","journal-title":"Can J Surg"},{"key":"1733_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216570","volume":"11","author":"C Pankratz","year":"2022","unstructured":"Pankratz\u00a0C, Cintean\u00a0R, Boitin\u00a0D, Hofmann\u00a0M, Dehner\u00a0C, Gebhard\u00a0F, Schuetze\u00a0K (2022) early surgical care of anticoagulated hip fracture patients is feasible: a retrospective chart review of hip fracture patients treated with hip arthroplasty within 24 hours. J\u00a0Clin Med 11:6570","journal-title":"J Clin Med"},{"issue":"suppl\u00a01","key":"1733_CR41","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1111\/jth.12949","volume":"13","author":"WH Dzik","year":"2015","unstructured":"Dzik\u00a0WH (2015) Reversal of oral factor\u00a0Xa inhibitors by prothrombin complex concentrates: a\u00a0re-appraisal. J\u00a0Thromb Haemost 13(suppl\u00a01):S187\u2013S194","journal-title":"J Thromb Haemost"},{"key":"1733_CR42","doi-asserted-by":"crossref","unstructured":"Schulman S, Gross PL, Ritchie B, Nihirniak S, Lin Y, Lieberman L, Carrier M, Crowther MA, Ghosh I, Lanzo-Langner A, Zondag M, and study investigators. Prothrombin complex concentrate for major bleeding on factor\u00a0Xa inhibitors: a\u00a0prospective cohort study. Thromb Haemost. 2018;118(5):842\u2013851.","DOI":"10.1055\/s-0038-1636541"},{"issue":"14","key":"1733_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly\u00a0SJ, Crowther\u00a0M, Eikelboom\u00a0JW, Gibson\u00a0CM, Curnutte\u00a0JT, Lawrence\u00a0JH, Yue\u00a0P, Bronson\u00a0MD, Lu\u00a0G, Conley\u00a0PB, Verhamme\u00a0P, Schmidt\u00a0J, Middeldorp\u00a0S, Cohen\u00a0AT, Beyer-Westendorf\u00a0J, Albaladeji\u00a0P, Sendon\u00a0JL, demchick\u00a0AM, Pallin\u00a0DJ, Concha\u00a0M, Goodman\u00a0S, Leeds\u00a0J, Souza\u00a0S, Siegal\u00a0DM, Zotova\u00a0E, Meeks\u00a0E, Ahmad\u00a0S, Nakamya\u00a0J, Milling\u00a0TJ, ANNEXA\u20114 Investigators (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Eng J Med 380(14):1226\u20131335","journal-title":"N Eng J Med"},{"key":"1733_CR44","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","volume":"390","author":"S Cononolly","year":"2024","unstructured":"Cononolly\u00a0S, Sharma\u00a0M, Cohen\u00a0AT, Demchuk\u00a0AM, Czlonkowska\u00a0A, Lindgren\u00a0A, Molina\u00a0C, Bereczki\u00a0D, Toni\u00a0D, Seiffge\u00a0D, Tanne\u00a0D, Sandset\u00a0EC, Tsivgoulis\u00a0G, Christensen\u00a0H, Beyer-Westendorf\u00a0J, Coutinho\u00a0J, Crowther\u00a0M, Verhamme\u00a0P, Amarenco\u00a0P, Roine\u00a0R, Mikulik\u00a0R, Lemmens\u00a0R, Veltkamp\u00a0R, Middeldorp\u00a0S, Robinson\u00a0T, Miling\u00a0TJ Jr, Tedim-Cruz\u00a0V, Lang\u00a0V, Himmelmann\u00a0A, Ladenvall\u00a0P, Knutson\u00a0M, Ekholm\u00a0E, Law\u00a0A, Taylor\u00a0A, Karyakina\u00a0T, Xu\u00a0L, Tsiplova\u00a0K, Poli\u00a0S, Kallm\u00fcnzer\u00a0B, Gumbinger\u00a0C, Shoamanesh\u00a0A, ANNEXA\u2011I Invesitgators (2024) Andexanet for Factor\u00a0Xa inhibitor associated acute intracerebral hemorrhage. N Engl J Med 390:1745\u20131755","journal-title":"N Engl J Med"},{"issue":"3","key":"1733_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40263-024-01071-6","volume":"38","author":"S Frol","year":"2024","unstructured":"Frol\u00a0S, Oblak\u00a0JP, Sabovic\u00a0M, Kermer (2024) Andexanet alfa: What have we learned from clinical trials and real-world data. CNS Drugs 38(3):163\u2013168","journal-title":"CNS Drugs"},{"key":"1733_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.thromres.2023.05.020","volume":"228","author":"SFB van der Horst","year":"2023","unstructured":"van der Horst\u00a0SFB, Martens\u00a0ESL, den Exter\u00a0PL, Bos\u00a0MHA, van Mens\u00a0TE, Huisman\u00a0MV, Klok\u00a0FA (2023) Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes. Thromb Res 228:21\u201332","journal-title":"Thromb Res"},{"issue":"24","key":"1733_CR47","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","volume":"77","author":"A Gomez-Outes","year":"2021","unstructured":"Gomez-Outes\u00a0A, Alcubilla\u00a0P, Calvo-Rojas\u00a0G, Terleira-Fernandez\u00a0AI, Suarez-Gea\u00a0L, Lecumberri\u00a0R, Vargas-Castrillon\u00a0E (2021) Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J\u00a0Am Coll Cardiol 77(24):2987\u20133001","journal-title":"J Am Coll Cardiol"},{"key":"1733_CR48","doi-asserted-by":"crossref","unstructured":"Haemstar Collaborators, Buka RJ, Nicolson PLR. A\u00a0UK-wide analysis of 2265 patients receiving a\u00a0reversal agent for dirct oral anticoagulant-associated bleeding. J\u00a0Thromb Haemost 2025; https:\/\/doi.org\/10.1016\/j.jtha.2025.11.003.","DOI":"10.1016\/j.jtha.2025.11.003"},{"key":"1733_CR49","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) (2020) Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten-Gesamtnovelle 2020. https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/_old-files\/downloads\/pdf-Ordner\/MuE\/Querschnitts-Leitlinien_BAEK_zur_Therapie_mit_Blutkomponenten_und_Plasmaderivaten-Gesamtnovelle_2020.pdf. Zugegriffen: 9. Apr. 2026"},{"issue":"3","key":"1733_CR50","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s11239-022-02695-5","volume":"54","author":"AS Go","year":"2022","unstructured":"Go\u00a0AS, Leong\u00a0TK, Sung\u00a0SH, Wie\u00a0R, Harrison\u00a0TN, Gupta\u00a0N, Baker\u00a0N, Goldstein\u00a0B, Ataher\u00a0Q, Solomon\u00a0MD, Reynolds\u00a0K, fort he REVERSAL study et\u00a0al (2022) Thromboembolism after treatment with 4\u2011factor prothrombin complex concentrate or plasma for warfarin-related bleeding. J\u00a0Thromb Thrombolysis 54(3):470\u2013479. https:\/\/doi.org\/10.1007\/s11239-022-02695-5","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"1733_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/cc13982","volume":"18","author":"H Sch\u00f6chl","year":"2014","unstructured":"Sch\u00f6chl\u00a0H, Voelckel\u00a0W, Maegele\u00a0M, Kirchmair\u00a0L, Schlimp\u00a0CJ (2014) Endogenous thrombin potential following hemostatic therapy with 4\u2011factor prothrombin complex concentrate: a\u00a07-day observational study of trauma patients. Crit Care 18(4):R147","journal-title":"Crit Care"}],"container-title":["Die Unfallchirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00113-026-01733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00113-026-01733-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00113-026-01733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:09:49Z","timestamp":1790176189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00113-026-01733-8"}},"subtitle":["Ein \u00dcberblick zum perioperativen Management","Review of perioperative management"],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s00113-026-01733-8","relation":{},"ISSN":["2731-7021","2731-703X"],"issn-type":[{"value":"2731-7021","type":"print"},{"value":"2731-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Christoffel gibt an, dass kein Interessenkonflikt besteht. M.\u00a0Maegele erhielt in der Vergangenheit Honorare und Unterst\u00fctzung f\u00fcr die Teilnahme an Advisory Boards, Vortragst\u00e4tigkeiten und wissenschaftliche Arbeiten von folgenden Firmen: Abbott, Astra Zeneca, Baxter, Bayer, Biotest, CSL Behring, Griffolds, IL-Werfen, LFB Biomedicaments, Portola Inc und TEM International.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}